Abbott Laboratories announced its financial results for the third quarter ended September 30, 2026. The company reported total reported sales of $13.013 billion for the quarter, representing a 14.5 percent increase compared to the same period in the prior year. On a comparable basis, which excludes the impact of foreign exchange and revenue from a competitor agreement, sales grew by 7.0 percent.
For the third quarter, Abbott reported GAAP diluted earnings per share of $0.53 and adjusted diluted earnings per share of $1.42. The adjusted figure excludes specified items such as acquisition-related expenses, legal settlements, restructuring actions, and stock-based compensation.
Guidance for the full year 2026 was reaffirmed. Abbott projects full-year comparable sales growth to be approximately 6.0 percent. The company also affirmed the midpoint of its previously provided adjusted diluted EPS guidance range, tightening the range to $5.50 to $5.55. Additionally, the company projects fourth-quarter 2026 adjusted diluted EPS to be between $1.62 and $1.67.
On a geographic basis, U.S. sales for the quarter increased 28.0 percent on a reported basis, while international sales increased 6.2 percent. The company’s business segments showed varied performance, with Diagnostics reporting a 46.7 percent reported sales increase and Established Pharmaceuticals reporting a 6.8 percent increase.
During the quarter, Abbott announced several new product approvals and launches, including the FDA approval for the Libre Duo dual glucose-ketone biowearable sensor and the TactiFlex Duo Ablation Catheter. The company also launched SimpleScreen CRC, a blood-based colorectal cancer screening test.
Abbott’s board of directors declared a quarterly dividend of $0.63 per share on September 17, 2026. This dividend is payable on November 16, 2026, to shareholders of record as of October 15, 2026.
